Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma

NCT02270034

Last updated date
Study Location
Institut Català D'Oncologia L'Hospitalet (Ico)
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glioblastoma Multiforme (Grade IV) of Cerebellum
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Ability to understand and the willingness to sign a written informed consent document.

2. Male or Female ≥18 years old and ≤ 70 years old

3. Newly diagnosed glioblastoma (GB) confirmed by biopsy or resection 4-7 weeks before registration.

4. Patients must have at least 15 unstained slides or 1 tissue block (frozen or paraffin embedded) available from a prior biopsy or surgery (archival tumor material).

5. Patients must have sufficient time for recovery from prior surgery (at least 4 weeks).

6. Karnofsky Performance Score (KPS) ≥ 60%.

7. Adequate hematologic function: Hemoglobin ≥ 10 g/dL, Leukocytes > 3,000/mcL, absolute neutrophil count (UNL) ≥ 1,500 cells/ul, platelets ≥ 100,000 cells/ul.

8. Adequate liver function: Bilirubin ≤ 2 X upper limit of normal (ULN); aspartate aminotrasferase (AST) (SGOT) ≤ 2.5 X ULN

9. Creatinine within normal institutional limits or creatinine clearance > 60 mL/min/1.73 m2l for subjects with creatinine levels above institutional normal.

10. The effects of crizotinib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or harrier method of birth control; abstinence; surgical sterilization) prior to study entry and for the duration of study participation and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. All female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 2 weeks prior to starting treatment.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Presence of extra-cranial metastatic disease.


2. Any prior radiotherapy (RT) or chemotheraphy (QT) treatment.


3. Patients must not have received prior Gliadel wafers.


4. The use of enzyme-inducing antiepileptic drugs will not be allowed. Those patients
taking enzyme-inducing antiepileptic drugs required a 7-day washout period before
registration.


5. Any surgery (not including minor diagnostic procedures such as lymph node biopsy)
within 2 weeks of baseline disease assessments; or not fully recovered from any side
effects of previous procedures.


6. Any clinically significant gastrointestinal abnormalities, which may impair intake,
transit or absorption of the study drug, such as the inability to take oral medication
in tablet form.


7. Any psychiatric or cognitive disorder that would limit the understanding or rendering
of informed consent and/or compromise compliance with the requirements of this
protocol.


8. Uncontrolled or significant cardiovascular disease, including:


- A myocardial infarction within 12 months;


- Uncontrolled angina within 6 months;


- Congestive heart failure within 6 months;


- Diagnosed or suspected congenital long QT syndrome;


- Any history of clinically significant ventricular arrhythmias (such as
ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);


- Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (>470 msec);


- Any history of second or third degree heart block (may be eligible if currently
have a pacemaker);


- Heart rate <50/minute on pre-entry electrocardiogram;


- Uncontrolled hypertension.


9. Any patient with a history of significant cardiovascular disease, even if currently
controlled, or who has signs or symptoms suggesting impaired left ventricular function
in the judgment of the investigator must have a screening left ventricular ejection
fraction (LVEF) evaluation by ECHO or angyography (MUGA). Patients with LVEF
measurements below local institutional lower limit of normal or less than 50% will not
be eligible.


10. Individuals with a history of a different malignancy are ineligible except for the
following circumstances: Individuals with a history of other malignancies are eligible
if they have been disease-free for at least 3 years and are deemed by the investigator
to be at low risk for recurrence of that malignancy. Individuals with the following
cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer
in situ, and basal cell or squamous cell carcinoma of the skin. Patients will not be
eligible if they have evidence of other malignancy requiring therapy other than
surgery within the last 3 years.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Glioblastoma Multiforme (Grade IV) of CerebellumStudy to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
NCT02270034
  1. L'Hospitalet de Llobregat, Barcelona
  2. Barcelona,
  3. Barcelona,
  4. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
Official Title  ICMJE Phase Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate the Safety and Activity of the Combination of Crizotinib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Brief Summary This multicenter, open-label, phase Ib trial aims to assess the safety and activity and safety of crizotinib (in combination with radiotherapy and temozolomide) in adult patients with newly diagnosed glioblastoma.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Glioblastoma Multiforme (Grade IV) of Cerebellum
Intervention  ICMJE Drug: Crizotinib
Crizotinib is added to Stupp method
Study Arms  ICMJE Experimental: Cohort crizotinib
Combination of crizotinib with temozolomide and radiotherapy following Stupp regime
Intervention: Drug: Crizotinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: October 17, 2014)
24
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 2020
Actual Primary Completion Date June 13, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Ability to understand and the willingness to sign a written informed consent document.
  2. Male or Female ?18 years old and ? 70 years old
  3. Newly diagnosed glioblastoma (GB) confirmed by biopsy or resection 4-7 weeks before registration.
  4. Patients must have at least 15 unstained slides or 1 tissue block (frozen or paraffin embedded) available from a prior biopsy or surgery (archival tumor material).
  5. Patients must have sufficient time for recovery from prior surgery (at least 4 weeks).
  6. Karnofsky Performance Score (KPS) ? 60%.
  7. Adequate hematologic function: Hemoglobin ? 10 g/dL, Leukocytes > 3,000/mcL, absolute neutrophil count (UNL) ? 1,500 cells/ul, platelets ? 100,000 cells/ul.
  8. Adequate liver function: Bilirubin ? 2 X upper limit of normal (ULN); aspartate aminotrasferase (AST) (SGOT) ? 2.5 X ULN
  9. Creatinine within normal institutional limits or creatinine clearance > 60 mL/min/1.73 m2l for subjects with creatinine levels above institutional normal.
  10. The effects of crizotinib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or harrier method of birth control; abstinence; surgical sterilization) prior to study entry and for the duration of study participation and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. All female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 2 weeks prior to starting treatment.

Exclusion Criteria:

  1. Presence of extra-cranial metastatic disease.
  2. Any prior radiotherapy (RT) or chemotheraphy (QT) treatment.
  3. Patients must not have received prior Gliadel wafers.
  4. The use of enzyme-inducing antiepileptic drugs will not be allowed. Those patients taking enzyme-inducing antiepileptic drugs required a 7-day washout period before registration.
  5. Any surgery (not including minor diagnostic procedures such as lymph node biopsy) within 2 weeks of baseline disease assessments; or not fully recovered from any side effects of previous procedures.
  6. Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drug, such as the inability to take oral medication in tablet form.
  7. Any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this protocol.
  8. Uncontrolled or significant cardiovascular disease, including:

    • A myocardial infarction within 12 months;
    • Uncontrolled angina within 6 months;
    • Congestive heart failure within 6 months;
    • Diagnosed or suspected congenital long QT syndrome;
    • Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);
    • Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (>470 msec);
    • Any history of second or third degree heart block (may be eligible if currently have a pacemaker);
    • Heart rate <50/minute on pre-entry electrocardiogram;
    • Uncontrolled hypertension.
  9. Any patient with a history of significant cardiovascular disease, even if currently controlled, or who has signs or symptoms suggesting impaired left ventricular function in the judgment of the investigator must have a screening left ventricular ejection fraction (LVEF) evaluation by ECHO or angyography (MUGA). Patients with LVEF measurements below local institutional lower limit of normal or less than 50% will not be eligible.
  10. Individuals with a history of a different malignancy are ineligible except for the following circumstances: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin. Patients will not be eligible if they have evidence of other malignancy requiring therapy other than surgery within the last 3 years.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02270034
Other Study ID Numbers  ICMJE GEINO 1402
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Grupo Español de Investigación en Neurooncología
Study Sponsor  ICMJE Grupo Español de Investigación en Neurooncología
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair:Juan Manuel Sepúlveda, MDHospital 12 de Octubre
Study Chair:María Martínez, MDHospital del Mar
PRS Account Grupo Español de Investigación en Neurooncología
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP